Carlos Reyes-Moreno

Dr. Carlos Reyes-Moreno

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2014 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
ADAngham Dallagi
Angham Dallagi
JGJulie Girouard
Julie Girouard
JHJovane Hamelin-Morrissette
Jovane Hamelin-Morrissette
RDRachel Dadzie
Rachel Dadzie
LLLaetitia Laurent
Laetitia Laurent
Carlos Reyes-MorenoCarlos Reyes-Moreno
Carlos Reyes-Moreno

17 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
APAlexis Paquin
Alexis Paquin
Carlos Reyes-MorenoCarlos Reyes-Moreno
Carlos Reyes-Moreno
GBGervais Bérubé
Gervais Bérubé
The design of C2-symmetric biologically active molecules is a subject of interest to the scientific community. It provides the possibility of discovering medicine with higher biological potential than the parent drugs. Such molecules are generally produced by classic chemistry, considering the shortness of reaction sequence and the efficacy for each step. This review describes and analyzes recent advances in the field and emphasizes selected C2-symmetric molecules (or axial symmetric molecules) made during the last 10 years. However, the description of the dimers is contextualized by prior work allowing its development, and they are categorized by their structure and/or by their properties. Hence, this review presents dimers composed of steroids, sugars, and nucleosides; known and synthetic anticancer agents; polyphenol compounds; terpenes, known and synthetic antibacterial agents; and natural products. A special focus on the anticancer potential of the dimers transpires throughout the review, notwithstanding their structure and/or primary biological properties.

1 February 2012 in Biology of Reproduction
Verified
Journal Article
Closed access
PDF file
KLKaty Leduc
Katy Leduc
VBVincent Bourassa
Vincent Bourassa
ÉAÉric Asselin
Éric Asselin
PLPierre Leclerc
Pierre Leclerc
JLJulie Lafond
Julie Lafond
Carlos Reyes-MorenoCarlos Reyes-Moreno
Carlos Reyes-Moreno
It is well established that syncytium formation involves the fusion of mononucleated trophoblasts into a multinucleated structure and the secretion of hormonal factors, such as human chorionic gonadotropin (hCG). These morphological and biochemical changes are regulated by a plethora of ligands, which upon binding to specific receptors trigger the activation of many signaling pathways, such as janus kinase/signal transducer and activator of transcription (JAK/STAT) and the mitogen-activated protein (MAP) kinase extracellular signal-regulated kinases 1 and 2 (MAPK3/1). We used the forskolin-induced syncytialization of trophoblastlike BeWo cells to characterize at the cellular level the effect mediated by leukemia inhibitory factor (LIF) on trophoblast differentiation and to describe its action at the molecular level. Forskolin induces both hCG secretion and BeWo cell syncytial fusion. Although LIF had no effect on the undifferentiated state of the cells, the cytokine generated a strong reduction in forskolin-induced hCG release. In contrast to its effect on hCG secretion, LIF exerts a synergistic effect toward forskolin-induced fusion. LIF reduced hormonal production through a STAT1- and STAT3-dependent mechanism, whereas MAPK3/1 was not involved in this process. However, both types of signaling molecules were required to mediate the action of LIF in forskolin-induced cell fusion. These data provide novel insights into the regulation of trophoblast cell differentiation by LIF and describe for the first time the molecular mechanism underlying the effect of the cytokine.

1 April 2020 in Molecular Immunology
Verified
Journal Article
Closed access
JHJovane Hamelin-Morrissette
Jovane Hamelin-Morrissette
ADAngham Dallagi
Angham Dallagi
JGJulie Girouard
Julie Girouard
MRMarion Ravelojaona
Marion Ravelojaona
YOYassine Oufqir
Yassine Oufqir
Carlos Reyes-MorenoCarlos Reyes-Moreno
Carlos Reyes-Moreno

28 February 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
MVMaxime Veillette
Maxime Veillette
KBKatsiaryna Bichel
Katsiaryna Bichel
PPPaulina Pawlica
Paulina Pawlica
SFStefan M V Freund
Stefan M V Freund
MPMélodie B Plourde
Mélodie B Plourde
LBLionel Berthoux
Lionel Berthoux
HIV-1 is inhibited early after entry into cells expressing some simian orthologues of the tripartite motif protein family member TRIM5α. Mutants of the human orthologue (TRIM5αhu) can also provide protection against HIV-1. The host protein cyclophilin A (CypA) binds incoming HIV-1 capsid (CA) proteins and enhances early stages of HIV-1 replication by unknown mechanisms. On the other hand, the CA-CypA interaction is known to increase HIV-1 susceptibility to restriction by TRIM5α. Previously, the mutation V86M in the CypA-binding loop of HIV-1 CA was found to be selected upon serial passaging of HIV-1 in cells expressing Rhesus macaque TRIM5α (TRIM5αrh). The objectives of this study were (i) to analyze whether V86M CA allows HIV-1 to escape mutants of TRIM5αhu, and (ii) to characterize the role of CypA in the resistance to TRIM5α conferred by V86M.

1 June 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JGJulie Girouard
Julie Girouard
DBDenise Belgorosky
Denise Belgorosky
JHJovane Hamelin-Morrissette
Jovane Hamelin-Morrissette
VBValerie Boulanger
Valerie Boulanger
EDErnesto D'Orio
Ernesto D'Orio
Carlos Reyes-MorenoCarlos Reyes-Moreno
Carlos Reyes-Moreno